Advertisement

Topics

Effector, Pfizer and Merck to initiate Phase II combination trial for colorectal cancer

19:00 EDT 20 Jun 2017 | Net Resources International

Effector Therapeutics has signed a clinical collaboration and supply agreement with Pfizer and Merck to initiate a Phase II clinical trial of immuno-oncology drugs combination to treat microsatellite stable colorectal cancer (CRC) patients.

Original Article: Effector, Pfizer and Merck to initiate Phase II combination trial for colorectal cancer

NEXT ARTICLE

More From BioPortfolio on "Effector, Pfizer and Merck to initiate Phase II combination trial for colorectal cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...